arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT US Healthcare & Life Sciences Summit

Facing the Tidal Wave: Risk and Opportunity in a Shifting Healthcare Landscape

New York |
Speakers include:
David Blumenthal

David Blumenthal

The Commonwealth Fund

Robert Henkel

Robert Henkel

Ascension Health

Michelle Larkin

Michelle Larkin

Robert Wood Johnson Foundation


The US healthcare industry is experiencing a period of profound change. A new Republican- led government is in place with a popular mandate to ‘repeal and replace’ many of the reforms that have transformed the industry in recent years, and healthcare leaders will need to adjust strategies to the wave of new polices and regulations emanating from Washington. At a more grass roots, operational level, however, new payment and delivery models are fundamentally reshaping how the industry conducts its business. Traditional boundaries between healthcare and life sciences businesses and professions are being dismantled. Meanwhile, new science and technology-from drones to the microbiome and robotics-are expanding the realm of opportunities for the industry.  How will the future unfold?

The FT US Healthcare and Life Sciences Summit, now its sixth successful year, will bring together industry leaders from across the healthcare and life sciences continuum to explore the major transformations ahead.

Topics for discussion will include:

  • US Healthcare reform: risk and opportunity in the new health economy
  • How will value transform the business of health?
  • Addressing social determinants of health-the next big healthcare challenge
  • Skills and leadership: What will the healthcare workforce of the future look like?
  • Is the future of healthcare virtual? Prospects for home care and telehealth
  • Beyond genomics: the next big Innovations on the frontiers of science, technology and medicine

Click here to view videos and photographs from the  FT US Healthcare & Life Sciences Summit 2016.

fallback Add to my Calendar 05/18/2017 08:00:0005/18/2017 17:20:00trueFT US Healthcare & Life Sciences SummitThe US healthcare industry is experiencing a period of profound change. A new Republican- led government is in place with a popular mandate to ‘repeal and replace’ many of the reforms that have transformed the industry in recent years, and healthcare leaders will need to adjust strategies to the wave of new polices and regulations emanating from Washington. At a more grass roots, operational level, however, new payment and delivery models are fundamentally reshaping how the industry conducts its business. Traditional boundaries between healthcare and life sciences businesses and professions are being dismantled. Meanwhile, new science and technology-from drones to the microbiome and robotics-are expanding the realm of opportunities for the industry.  How will the future unfold?The FT US Healthcare and Life Sciences Summit, now its sixth successful year, will bring together industry leaders from across the healthcare and life sciences continuum to explore the major transformations ahead.Topics for discussion will include:US Healthcare reform: risk and opportunity in the new health economyHow will value transform the business of health?Addressing social determinants of health-the next big healthcare challengeSkills and leadership: What will the healthcare workforce of the future look like?Is the future of healthcare virtual? Prospects for home care and telehealthBeyond genomics: the next big Innovations on the frontiers of science, technology and medicineClick  here to view videos and photographs from the  FT US Healthcare & Life Sciences Summit 2016.FT-US-Healthcare-&-Life-Sciences-Summit29784a2551e5e1b56db4df2b4b97a30dMM/DD/YYYY

Countdown Ticker


Hear from past attendees:


"This summit has become the Davos or The TED conference for healthcare and life sciences.The best minds having meaningful discussions." - Lawrence Gottlieb, President & CEO, Hudson Valley Economic Development Corporation

"Best array of speakers, balanced panels with provocative discussions. The day seemed to go by in a snap. Didn't want it to end. Wanted to learn more." - James Lebret, Physician, NYU Medical Centre

"Subject matter experts - depth and breadth of knowledge across entire eco-system, FT does an excellent job with the selection of speakers and conducting the panel discussions." - Anonymous


Speakers (33)

David Blumenthal

David Blumenthal

President and CEO
The Commonwealth Fund

David Blumenthal, MD, MPP became President and CEO of the Commonwealth Fund, a national health care philanthropy based in New York City, in January, 2013. Previously, he served as Chief Health Information and Innovation Officer at Partners Health System in Boston, MA, and was Samuel O. Their Professor of Medicine and Professor of Health Care Policy at Massachusetts General Hospital/ Harvard Medical School. From 2009 to 2011, Dr Blumenthal was the National Coordinator for Health Information Technology under President Barack Obama. In this role he was charged with building an interoperable, private and secure nationwide health information system and supporting the widespread, meaningful use of health IT. Prior to that, Dr Blumenthal was a practicing primary care physician, Director of the Institute for Health Policy, and Professor of Medicine and Health policy at Massachusetts General Hospital/Partners Healthcare System and Harvard Medical School. As a renowned health services researcher and national authority on health IT adoption, Dr Blumenthal has authored over 250 scholarly publications, including the seminal studies on the adoption and use of health information technology in the United States. Dr Blumenthal received his undergraduate, medical and public policy degrees from Harvard University and completed his residency in internal medicine at Massachusetts General Hospital.

Robert Henkel

Robert Henkel

President and Chief Executive Officer
Ascension Health
Michelle Larkin

Michelle Larkin

Associate Chief of Staff and Associate Vice President-Program
Robert Wood Johnson Foundation

Michelle Larkin, Associate Chief of Staff and Associate Vice President – Program, directs program and administrative activities of the Robert Wood Johnson Foundation. She helps shape the Foundation’s strategies, policies and impact, building a culture of health for our nation where everyone has the opportunity to live healthier lives, no matter where they live or how much they make.

Before joining the Foundation, Ms Larkin worked as an oncology nurse at the University of Maryland Medical System in Baltimore, where she experienced the opportunities, challenges, and rewards of bedside nursing. She left bedside nursing to focus on population health improvement through systems, law and policy change at the federal level. She has worked at the Office on Smoking and Health, Centers for Disease Control and Prevention (CDC) and the US Senate Labor and Human Resources Committee, as well as the Office on Smoking and Health, CDC, in Washington, D.C.

Ms Larkin received a JD from Seton Hall University School of Law, an MS in nursing/health policy from the University of Maryland and a BSN from the University of Pennsylvania.

Noubar Afeyan

Noubar Afeyan

Senior Managing Partner and CEO
Flagship Pioneering

Noubar Afeyan leads Flagship Pioneering, a firm that conceives, creates, resources and develops first-in-category life science ventures. Throughout his long-standing career as inventor, entrepreneur, CEO and venture capitalist, Mr Afeyan has co-founded and built more than 40 companies, including Moderna Therapeutics and Seres Therapeutics. He serves on a number of corporate boards, including those of Codiak Biosciences, Evelo BioSciences, Joule Unlimited and Axcella. Mr Afeyan received a 2012 Technology Pioneer award from the World Economic Forum in recognition of the breakthrough solar fuel technology developed by Joule Unlimited. He has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum, is a member of the Meta-Council on Emerging Technologies, and currently sits on the MIT Corporation Board. He also received the Ellis Island Medal of Honor, which recognizes Americans who have distinguished themselves as US citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. Mr Afeyan holds a PhD. from MIT, has authored numerous scientific publications, and has received patents for his work across multiple fields.

Daniel Barchi

Daniel Barchi

Senior Vice President and Chief Information Officer
New York Presbyterian Hospital

Daniel Barchi is Senior Vice President and Chief Information Officer of New York-Presbyterian, one of the largest healthcare providers in the US and the University Hospital of Columbia and Weill Cornell. He leads a team of more than 700 informatics and technology specialists who deliver the tools and data that physicians and nurses use to deliver acute care and manage population health.  Before joining New York-Presbyterian, Mr Barchi was Chief Information Officer of the Yale School of Medicine and Yale-New Haven Health System. In that role he established nation-leading analytics and clinical research technology practices and led a $300 M Electronic Medical Record project. Before joining Yale, he was Senior Vice President and CIO of the $1.4bn Carilion Health System, and led the integration of Carilion’s operations though implementation of Electronic Medical Records at seven hospitals and 140 physician practices.

Mr Barchi was previously President of the Carilion Biomedical Institute and Director of Technology and Engineering for MCI WorldCom. In both roles, he was appointed as CEO, COO, and Chief Restructuring Officer of privately held and venture-backed companies in the healthcare and technology industries. Earlier, Mr Barchi served as MCI's Director of Global Project Management responsible for product deployment in Europe, Asia, and the Americas. Daniel began his career as a US.Naval officer at sea on guided-missile cruisers. During his service, he was awarded the Navy Commendation Medal, the Southeast Asia Service Medal for Iraq operations in the Red Sea, and the NATO Service Medal for Bosnia operations in the Adriatic Sea.

Mr Barchi holds a Bachelor of Science from Annapolis, the US Naval Academy, and a Master of Engineering Management from Old Dominion University. He is faculty at Yale University.

Josh  Bruno

Josh Bruno

Founder and CEO

Josh Bruno is Founder and CEO of Hometeam, Mr Bruno founded Hometeam when his family struggled to care for his 93-year-old grandfather. He believes that home care should go beyond the basics to provide a safe, reliable, and interactive service that creates happier days for seniors. Prior to Hometeam, Mr Bruno worked as an investor, operator, and engineer at companies to include Bain Ventures, Bain & Co, and Yahoo.

Tanisha Carino

Tanisha Carino

Vice President, US Public Policy

Tanisha Carino serves as Vice President, US Public Policy at GlaxoSmithKline, which is committed to helping people do more, feel better and live longer. In her role, Dr Carino promotes public policies in the best interest of patients and the public’s health.  She joined the company from Avalere Health, a strategic health care advisory company, where she oversaw advisory and research services for the nation’s leading life sciences companies as Executive Vice President. Dr Carino brings over 15 years of experience in consulting, management, health policy and strategy development across government, industry and academia. She is a recognized thought leader in the evolving US regulatory environment, market access and commercial trends, as well as health technology and evidence-based medicine. Dr Carino has a PhD in Health Policy from Johns Hopkins University and is a Fulbright scholar. She serves as an associate faculty member in the Johns Hopkins Bloomberg School of Public Health and is a board member of Bread for the City in Washington, District of Columbia.

Steve Cutler

Steve Cutler


Dr Steve Cutler was appointed Chief Executive Officer of ICON in March 2017, having previously served as Chief Operating Officer. He is also a member of ICON’s Board of Directors. Dr Cutler joined ICON in 2011 and served as Group President, Clinical Research Services until his appointment as Chief Operating Officer in 2014. Dr. Cutler has over 28 years of pharmaceutical industry and CRO experience. Prior to ICON, he was Chief Executive officer of Kendle and oversaw the sale of the company to INC Research. Prior to Kendle, Dr Cutler held various operational and general management roles in both Quintiles and Sandoz (Novartis).

Jeffrey Dachis

Jeffrey Dachis

Founder and CEO
One Drop

Jeff​ Dachis is the CEO and Founder of One Drop, a simple, powerful and convenient mobile platform for managing diabetes, born from his own experience as a Type 1 person with diabetes. His desire to bring the quantifi​ed self movement, internet of things, big data and mobile computing to people with diabetes in a simple, fully integrated solution led him to create the award winning One Drop platform. Prior to One Drop, Mr Dachis was ​the Founder, CEO and Chairman of Dachis Group and drove the eventual strategic sale to Sprinklr, the leading social experience management platform. Mr Dachs is also the Co-Founder, former CEO and Chairman of Razorfi​sh, the world’s largest digital marketing solutions firm​ where he bootstrapped the company and led it through its successful $55m IPO and eventual $6bn market capitalization. ​

Joe Damore

Joe Damore

Vice President, Population Health Management

Joe Damore is Vice President, Population Health Management, Premier. In this role, he is responsible for a team of health care consultants who assist hospitals, physicians and health systems in developing integrated health systems and in implementing accountable care organizations. He provides consultative assistance to Population Health Collaborative members and advises numerous health care organizations in areas such as strategic business planning, clinical integration and quality and financial improvement.

Prior to joining Premier, Mr Damore served as CEO of Mission Health System from 2004 to early 2010 and the Sparrow Health System from 1990 to 2004. Prior to his tenure as a CEO, he served as an executive with Mercy Health Services (Trinity Health), Western Reserve Care System and Greenville (S.C.) Health System. He also was President of JFD Consulting, LLC, an advisory firm focused on helping hospitals and health systems prepare for health care reform and in the development of integrated health systems and accountable care organizations. His entire 35 year career as a health care leader has focused on building and developing regional integrated health systems, including integrating comprehensive delivery systems and health plans. In addition, he helped founded and served as Executive Director of a new national coalition of hospital and health system (not for profit) sponsored health plans (HHP). Mr Damore holds a BA degree from Thiel College in Greenville, PA, and a Master’s degree in Health Administration from The Ohio State University. He is a Fellow of the American College of Healthcare Executives and most recently served as Board Chair of The Ohio State University Alumni Association, on the Board of Directors of the University of North Carolina-Asheville and on the board of the Alliance for the Advancement of nonprofit Health Care.

The Honorable Tom  Daschle

The Honorable Tom Daschle

Founder and CEO
The Daschle Group

Senator Daschle is the founder and CEO of The Daschle Group, a public policy advisory of Baker Donelson. Senator Daschle served his home state, South Dakota, in the US House of Representatives from 1979 until 1987 and in the US Senate from 1987 to 2005. He is one of only two senators to have served twice as both majority and minority leader. In addition, Senator Daschle is Chair of the Board of Directors at the Center for American Progress, Vice-Chair for the National Democratic Institute and a Co-Founder of the Bipartisan Policy Center. He is the author of Like No Other Time: The 107th Congress and the Two Years That Changed America Forever; Critical: What We Can Do About the Health-Care Crisis; Getting It Done: How Obama and Congress Finally Broke the Stalemate to Make Way for Health Care Reform, and U.S. Senate: Fundamentals of American Government. He co- authored his most recent book, Crisis Point, with former Senator Trent Lott.

Damon Francis

Damon Francis

Chief Medical Officer
Health Leads

Dr Damon Francis is Chief Medical Officer at Health Leads. He joined Health Leads after five years in the Alameda County Health Care Services Agency in the East San Francisco Bay Area, where he worked on all aspects of the Agency’s vision for “healthy people, places, policies and systems.” As Interim Director and Medical Director of Health Care for the Homeless, Dr Francis led the adoption and expansion of clinical models addressing the whole person including medical, behavioural, and social needs. Much of his work leveraged new funding opportunities under the Affordable Care Act. His roles in the program ranged from clinician to manager to payer, allowing him to experience both the bewildering complexity of health care payment models, and the awesome diversity of human resilience. Previously, Dr Francis served as the Medical Director of the Urban Male Health Initiative, where he worked to reduce health disparities affecting men of color, providing policy analysis and representing the public health department in cross-governmental initiatives and public-private partnerships related to housing, criminal justice, and clinical quality improvement. He also worked at the East Bay AIDS Center in Oakland, California, where he helped drive innovations such as marketing through social networks, providing strong peer supports, and involving patients in clinic design, each of which has led to improvements in care for a group that has historically been served very poorly by the healthcare system. Dr Francis is an Assistant Clinical Professor at the University of California, San Francisco, where he completed medical school and residency in primary care internal medicine and served as Chief Resident for the Internal Medicine Service at San Francisco General Hospital. His clinical experience since residency includes inpatient and outpatient practice in public, private, and academic settings, and he continues to provide urgent care at a community clinic in Oakland.

Dedi Gilad

Dedi Gilad

Tyto Care

Dedi Gilad is CEO and Co-Founder, Tyto Care. With over 18 years of experience in leadership positions both in startups as well as global companies, Mr Gilad brings extensive knowledge and hands-on experience in R&D, marketing and operations of multi-disciplinary products in the fields of healthcare IT, enterprise systems, internet and SaaS. Before founding Tyto Care, Mr Gilad was General Manager at MDG Medical, Vice President of R&D at WorkplaceIQ (acquired by Siterra / Accruent) and Vice President of R&D at Aman Group. Mr Gilad earned an MBA and a BSc in Industrial Engineering from the Tel-Aviv University.

Douglas Henley

Douglas Henley

Executive Vice President and Chief Executive Officer
American Academy of Family Physicians

Douglas Henley serves as Executive Vice President and Chief Executive Officer for the American Academy of Family Physicians (AAFP). The AAFP is the medical specialty organization representing 124,900 family physicians and medical students nationwide. Mr Henley has served on the board of directors of the Patient-Centered Primary Care Collaborative since its founding and is the Immediate Past Chair. He served as a commissioner on the American Health Information Community, and was one of the inaugural commissioners of the Certification Commission for Healthcare Information Technology.  He is a past President of the AAFP (1995-1996). Mr Henley is a graduate of the University of North Carolina School of Medicine, Chapel Hill, and its’ family medicine residency program, is board certified by the American Board of Family Medicine and has the AAFP Degree of Fellow, a degree awarded to family physicians for distinguished service and continuing medical education.

Peter Keeling

Peter Keeling

Chief Executive Officer

Peter Keeling is Chief Executive Officer of Diaceutics, a global group of experts from the laboratory, diagnostic and pharmaceutical industries. Mr Keeling recognized early on that precision medicine would be an increasingly large part of the drug development paradigm, representing a shift in how the pharmaceutical industry operates. His role with Diaceutics complements over thirty years’ experience in international healthcare which began at GSK and Diagnology. He has operated and led companies and teams in the US, Europe, Asia and BRIC countries, inspiring product innovation and global launches while repeatedly delivering high corporate value growth for shareholders. Mr Keeling has spent two extended periods in applied industrial research, including a year at MIT’s Pharmaceutical Program at the Sloan School of Management in Boston. He has also been published widely in peer reviewed economic and precision medicine journals, is a seasoned speaker and is considered one of the world’s thought leaders in diagnostic launch commercialization in support of optimizing therapy.

Aaron  Kesselheim

Aaron Kesselheim

Associate Professor of Medicine
Harvard Medical School

Aaron. Kesselheim, MD JD MP, is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital (BWH). His work addresses a number of topics at the intersection of law, medicine, and ethics, including FDA regulatory policies and the approval process for prescription drugs and medical devices and the costs, availability and evidence-based use of prescription drugs. He graduated from Harvard College and received his postgraduate training at the University of Pennsylvania School of Medicine and Law School and most recently at the Harvard School of Public Health. He is Board Certified in Internal Medicine, and serves as a primary care physician at the Phyllis Jen Center for Primary Care at BWH. Within the Division, Professor Kesselheim created and leads the Program On Regulation, Therapeutics and Law (PORTAL), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes and regulatory practices and the law. Professor Kesselheim is a member of the New York State Bar and is a Patent Attorney.

David Lansky

David Lansky

Chief Executive Officer
Pacific Business Group on Health
Jeff  Marrazzo

Jeff Marrazzo

Spark Therapeutics

Jeff Marrazzo has led the creation and growth of Spark Therapeutics from a research center within the Children's Hospital of Philadelphia to a fully integrated gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable – until now. He also serves on Spark’s board of directors. Under Mr Marrazzo’s leadership, Spark has successfully completed the first randomized, controlled Phase 3 trial of an investigative gene therapy for a genetic disease and established human proof-of-concept of Spark’s gene therapy platform in both the retina and the liver. The company is currently preparing the first Biologics License Application submission for a gene therapy for a genetic disease in the US. During a career that has spanned the public and private sectors, Mr Marrazzo has consistently championed the potential benefits of precision medicine and healthcare reform for patients. Prior to Spark, he helped build and sell the first genetic testing benefit management and pharmacogenomics medicines company to CVS Caremark. Previously, Mr Marrazzo served as an advisor to former Pennsylvania Governor Edward G. Rendell, where he led reforms in the financing and delivery of healthcare. Mr Marrazzo received a BA. in Economics and BSE in Systems Science and Engineering from the University of Pennsylvania. He also holds a dual MBA / MPA from The Wharton School of the University of Pennsylvania and Harvard University, a program which he founded.

Robert McMahon

Robert McMahon

President, US Market

Bob McMahon is the President of Merck’s US Market, a region of the Global Human Health division. In this role, Mr McMahon leads a team of 4,000 employees responsible for all sales, marketing and business operations supporting the commercialization of pharmaceutical products promoted by Merck in the United States. The US is Merck’s largest market, with sales of more than $20 billion in 2014.  From 2012 until 2013, Mr McMahon served as Senior Vice President of Government Relations, Public Policy and Corporate Responsibility, where he was instrumental in shaping Merck’s response to the changing US healthcare environment, including the introduction of the Affordable Care Act (ACA). Over the course of his 33-year career, Mr McMahon has developed a reputation as a passionate, results-oriented leader. A CPA by training, Bob began his Merck career in finance and has since held a variety of commercial roles with both domestic and international responsibilities. With more than 25 years of experience in the US Market, Mr McMahon has led important launches for HIV, cardiovascular disease and diabetes. He also has been an architect and sponsor of organizational change and the evolution of the Merck commercial model over the last ten years.  Mr McMahon serves as a member of the Board of Trustees for the Children’s Inn at the National Institutes for Health, and the Dean’s Advisory Council for the Villanova School of Business. Before joining Merck, Mr McMahon worked for the Squibb Corporation and Arthur Andersen & Co. Mr McMahon is a graduate of Villanova University where he earned a Bachelor of Science degree in Accounting. 

Jim Meyers

Jim Meyers

Executive Vice President, Worldwide Commercial Operations

 Jim Meyers joined Gilead in 1996 and was appointed to his current role of Executive Vice President, Worldwide Commercial Operations, in November 2016. In this role, he is responsible for commercial activities in North America, Europe, Middle East, Australia and Japan. Mr Meyers began his career at Gilead as a Regional Sales Director, and subsequently held leadership positions within the US and North American Commercial Operations organization before being appointed Senior Vice President of North American Commercial Operations in 2007. Prior to Gilead, he held positions of increasing responsibility in sales, training, marketing and management with Zeneca Pharmaceuticals and Astra USA. Mr Meyers is a member of the boards of the Biotechnology Innovation Organization (BIO) and the California Life Sciences Association. He received his Bachelor's degree in Economics from Boston College.

Steve Miller

Steve Miller

Vice President and Chief Medical Officer
Express Scripts

Steve Miller is Senior Vice President & Chief Medical Officer, Express Scripts Since 2006, and is actively involved in developing the company’s clinical programmes and advocating for more affordable and accessible healthcare in the United States. He is a leader in the promotion of legislation to create a pathway at the U.S. Food and Drug Administration for the regulation of biosimilars. Prior to joining Express Scripts in 2005, Dr Miller was the Vice President and Chief Medical Officer at Barnes-Jewish Hospital, Washington University School of Medicine in St. Louis, Missouri. He received his medical degree from the University of Missouri- Kansas City, and he trained in the Pathology and Research fellowship at the University of Alabama at Birmingham, and in Cardiology at the University of California, San Francisco. Dr Miller also earned his MBA at the Olin School of Business at Washington University in St. Louis.

Dr Jose  Peña

Dr Jose Peña

Chief Executive Officer and Chief Medical Officer
Rio Grande Valley ACO
Anne Phelps

Anne Phelps

Principal, US Healthcare Regulatory Leader

Anne Phelps is a Deloitte Advisory Principal in the Life Sciences and Health Care practice of Deloitte & Touche LLP. She has over twenty-seven years of health care policy experience in a broad range of legislative and regulatory issues. Ms Phelps serves as a strategic business advisor to numerous health care stakeholders - including providers, payers, employers, life sciences companies, and investors - to help them navigate the complex health care regulatory environment and how it will impact their organizations. This involves understanding the regulatory landscape, interpreting the impact on the various stakeholders, and helping organizations scenario plan, formulate priorities, and execute their strategies.

Prior to her career in professional services, Ms Phelps served in the Bush Administration as a Special Assistant to the President as the Chief Health Policy Advisor to the President for the Domestic Policy Council and as the Executive Director of the 2004 Republican National Platform Committee. Earlier in her career, Ms Phelps worked on Capitol Hill in the United States Senate and at the National Institutes of Health in a variety of health policy and legislative roles.

Al Prieto

Al Prieto

Managing Partner, New York; Co-Global Practice Lead, Health
Egon Zehnder

Al Prieto is the Managing Partner of Egon Zehnder’s New York office, and also serves as the Co-Global Practice Leader of Egon Zehnder Health. The Health team serves enterprises across the business spectrum that are dedicated to improving the health and well-being of consumers around the world. In addition to leading engagements and driving strategy for the firm's work with global clients in healthcare and related sectors, he has responsibility for Egon Zehnder's professional advisory team based in NYC supporting metro area clients across all industry sectors and is actively involved in engagements at the CEO, Board, and C-Suite in these sectors. Mr Prieto’s 25-year career in the health sector spans corporate and entrepreneurial businesses as well as international boundaries. In the US. he founded InSite Clinical Trials, a biopharmaceutical clinical product development services firm later sold to United Healthcare. He then launched a series of novel healthcare delivery ventures including retail pharmacy-based health clinics, disease management services, and ancillary healthcare facilities. Partners in these ventures included leading US multispecialty physician practice groups, and corporations including Boots PLC in the UK. Previously, Mr Prieto served as Regional Business Director in Europe for AstraZeneca, and in this role was responsible for leading commercial operations across a 14-country territory spanning Central and Eastern Europe.  Mr Prieto earned a BS in Biology at Western Kentucky University and an MS in Management as a Sloan Fellow at London Business School.

Michael  Rea

Michael Rea

Founder and CEO
Rx Savings Solutions

Michael Rea founded Rx Savings Solutions in 2008 after routinely witnessing consumers struggling to pay for their medications. He noticed quickly at that time that consumers were paying much more than they needed to, which was attributable to a lack of information available to them. He set out on his mission to arm consumers with this information and add efficiency and transparency back into the world of pharmacy. Dr Rea has been involved with research surrounding pharmacy transparency for over 10 years. He received his Doctor of Pharmacy degree from Creighton University.

Jeffrey  Riley

Jeffrey Riley

Chief Executive Officer
President and Director Synthetic Biologics
Mario  Schlosser

Mario Schlosser

CEO & Co-Founder

Mario Schlosser is the CEO and co-founder of Oscar, a health-insurance start-up that is using technology, design, and data to help humanize and simplify healthcare. Previously, he co-founded the largest social gaming company in Latin America, where he led the company's analytics and game design practices. In an earlier position at Bridgewater Associates, Mr Schloesser developed analytical trading models as a Senior Investment Associate. Prior to Bridgewater, he worked as a consultant for McKinsey & Company in Europe, the US. and Brazil. As a visiting scholar at Stanford University, Mr Sclosser wrote and co-authored 10 computer science publications, including one of the most-cited computer science papers published in the past decade, in which he developed an algorithm to securely compute trust in randomized networks. Mr Sclosser holds a degree in Computer Science with highest distinction from the University of Hannover in Germany and an MBA from Harvard Business School.

Roy	 Schoenberg

Roy Schoenberg

American Well

Roy Schoenberg founded American Well in 2006 and currently oversees operations as the company’s President and Chief Executive Officer. He also serves on the Board of the American Telemedicine Association. Dr Schoenberg was instrumental in the development of the company’s core technology, a brokerage engine that connects patients and providers for telemedicine visits. Prior to American Well, Dr Schoenberg founded CareKey, a supplier of chronic condition management software. Following the acquisition of CareKey by TriZetto, Dr Schoenberg served as that company’s Chief Information Security Officer. He is an avid author and speaker in the areas of healthcare technology and Health IT policy. In 2013, he was appointed to the Federation of Medical Board’s task force delivering landmark guidelines for the ‘Appropriate use of Telehealth in Medical Practice’.In 2014, he received the American Telemedicine Association Industry award for Leadership in the field of Telemedicine. Dr Schoenberg holds an MD from the Hebrew University and an MPH from Harvard University.

Laura Schumacher

Laura Schumacher

Executive Vice President, External Affairs, General Counsel and Corporate Secretary

Laura Schumacher is Executive Vice President, External Affairs, General Counsel and Corporate Secretary, responsible for AbbVie’s externally-facing functions of Health Economics Outcomes Research, Government Affairs, Corporate Responsibility, Brand and Communications. She also leads all legal functions and Biotherapeutics Strategy.

Prior to AbbVie’s separation from Abbott, Ms Schumacher served as Executive Vice President, General Counsel and Secretary, where she also had responsibility for the Office of Ethics and Compliance.  Both at Abbott and AbbVie, Ms Schumacher has led Licensing & Acquisitions and Ventures and Early Stage Collaborations.

Ms Schumacher joined the company as a litigation attorney and has held various leadership positions, including Senior Vice President, Secretary and General Counsel, Vice President, Secretary and Deputy General Counsel and Divisional Vice President, Litigation. Prior to joining Abbott, Ms Schumacher was an associate attorney with the law firm Schiff, Hardin & Waite in Chicago.

Ms  Schumacher serves on the board of directors of General Dynamics and is a member of the National Association of Corporate Directors, American Bar Association, the Society of Corporate Secretaries and Governance Professionals, the Commercial Club of Chicago, the Economic Club of Chicago, the Chicago Network, the Chicago Club and the Notre Dame Law School Advisory Council.

She earned a Bachelor's degree in Business Administration from the University of Notre Dame and a Juris Doctorate from the University of Wisconsin at Madison.

Julie  Staudenmier

Julie Staudenmier

Senior Director Global Learning and Development

Julie Staudenmier is Senior Director, Global Learning and Development at Pfizer. In this role, she has responsibility for developing and executing Pfizer's global learning and leadership development strategy.  Global Learning &Development directly connects to Pfizer's strategic imperatives and contributes to the growth and development of leadership at every level, including individuals, managers, and senior leaders. Prior to joining Pfizer, Ms Staudenmier held executive level human resource positions at Boehringer Ingelheim, American Express, Sony, and TD Ameritrade. In these positions, she led initiatives in executive and leadership development, succession planning and talent management, corporate learning and development, talent acquisition, resource planning and organizational development. Earlier in her career, Ms Staudenmier  was a partner with Executive Development Associates (EDA), a boutique consulting firm focusing on strategic executive development. Ms Staudenmier has a Masters in Industrial/Organizational Psychology from Wayne State University and a BA in Psychology and Sociology from South Dakota State University.

Ramita  Tandon

Ramita Tandon

Executive Vice President, Commercialisation and Outcomes

Ramita Tandon is Executive Vice President, Commercialization & Outcomes Services, ICON, a position she has held since December 2015.In her current role, she leads the company’s Commercialization and Outcomes service area, which helps clients to optimize the value of drugs and medical devices through strategies and tactics that reflect evolving evidentiary, regulatory, and reimbursement requirements. She has been involved in the drug development industry for over 20 years with a focus on building new opportunities for various clinical research organizations. Ms Tandon is a recognized thought leader and provides regular industry commentary on areas including the late phase market, product commercialization, and bridging the silos between clinical and commercial groups to optimize product value. Ms Tandon’s passion and commitment in the commercial and outcomes domain stems from her belief that the commercial model is ripe for significant change and innovation and will continue to serve as a driving force in the overall healthcare ecosystem.

Dieter	 Weinand

Dieter Weinand

Member of the Board of Management and President, Pharmaceuticals

Dieter Weinand has been a member of the Board of Management and President of the Pharmaceuticals Division of Bayer AG, headquartered in Berlin, Germany, since January 1, 2016. He joined Bayer in August 2014 as head of the Pharmaceuticals Division. During a career stretching back over 25 years, he has held various positions in commercial, operational and strategic areas of the pharmaceutical industry. These included responsibilities spanning various therapeutic areas and geographies for companies such as Pfizer and Bristol-Myers Squibb. Mr Weinand earned an M.S. in Pharmacology and Toxicology from Long Island University, New York, and a BA. in biology from Concordia College, New York.

Frank   Westermann

Frank Westermann

Chief Executive Officer and Co-Founder

Chair and Moderators (3)

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Sarah  Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.

Sarah Thomas

Sarah Thomas

Managing Director, Deloitte Center for Health Solutions

Sarah Thomas is the Managing Director of the Deloitte Center for Health Solutions, part of Deloitte LLP’s Life Sciences and Health Care practice. As the leader of the Center, she drives the research agenda to inform stakeholders across the health care landscape about key trends and issues facing the industry. Ms Thomas was previously Vice President for Public Policy and Communications at the National Committee for Quality Assurance (NCQA), where she was responsible for the development of NCQA’s public policy strategy, its work with the federal and state government, as well as its media and communications operations. She also served as the director of the Public Policy Institute (PPI) Health Team at AARP. She oversaw AARP’s advocacy in areas of cost, access, and quality related to health care reform, Medicare, Medicaid, prescription drugs, private insurance, and public health. 

In addition to her nonprofit work, Ms Thomas has 14 years of experience in the federal government. She was Deputy Director at the Medicare Payment Advisory Commission (MedPAC) and served at the Congressional Budget Office and the Centers for Medicare and Medicaid Services (CMS). Ms Thomas has worked for national associations, in state government, and for the Advisory Board Company. She holds a M.S. in Health Policy and Management from the Harvard School of Public Health.

Agenda - 18th May

  • 8:00am
    Registration and Breakfast
  • 8:30am
    Breakfast Briefing: Leveraging diagnostics and analytics (Dx) to boost therapy return on investment - a 360° review

    With over $200bn of drug revenue already shaped by diagnostics and 70% of future pipelines biomarker enabled, the dependence of the future pharma business model on integrating diagnostics is no longer in question. However, this throws into sharp focus the readiness of the industry to understand and optimize the clinical diagnostic ecosystem underpinning every therapy launch. The question is no longer “which patients tested positive for a targeted therapy choice?” but rather “how many of the right patients were not tested and missed the treatment opportunity?”

    This briefing will quantify the missed treatment opportunity based on real time/real world US testing data, and discuss the readiness of the pharma industry to radically improve patient testing in support of improving outcomes and accessing higher return on personalised medicine investments.

    Peter Keeling, Chief Executive Officer, Diaceutics

  • 9:00am
    Opening Remarks from the Chair

    David Crow, Senior US Business Correspondent, Financial Times

  • 9:05am
    Opening Keynote Address

    Dieter Weinand, Member of the Board of Management and President Pharmaceuticals, Bayer 

  • 9:30am
    Panel: US Healthcare Reform: Risk and Opportunity in the New Health Economy

    With the Trump Presidential victory, and the Republican party now in control of the White House and both Houses of Congress, the stage looks set for a period of significant disruption and uncertainty for the healthcare and life sciences industry with the potential for the upending of many of the reforms and transformations which have reshaped the landscape of the industry in recent years. What can we expect in this next round of reforms? What will be the meat on the bones of ‘repeal and replace’? What will the changes mean for healthcare consumerism, healthcare delivery, the insurance market and for innovation, for instance? Will we continue to see progress regardless of the political context? How will the healthcare future in the US unfold? What are the opportunities and risks as we move forward with reforms, and the innovations which will are likely to have the greatest impact in future? How will the competitive landscape of the industry evolve in the post ACA world?

    David Blumenthal, President and CEO, The Commonwealth Fund
    Mario Schlosser, CEO & Co-Founder, Oscar
    The Honorable Tom Daschle, Founder and CEO, The Daschle Group
    Robert McMahon, President, US Market, Global Human Health, Merck
    Laura Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary, AbbVie

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 10:30am
    What is the Price of a Drug?

    The furor over drug prices in the US looks set to continue under the new Republican-led Administration, with little evidence of workable and politically acceptable solutions in sight. As prices rise, drugmakers are playing down their role, and are instead blaming the middlemen - the wholesalers, pharmacies and pharmacy benefit managers (PBMs)  - who take their own cut of the price. The rebate system, whereby PBMs take a percentage share of the rebates they win for purchasers, it is claimed, encourages price inflation. Value judgements,meanwhile, according to the pharma industry, are too often based on the wholesale price of the drug.  Is the current rebate system dysfunctional and in need of reform, or are the middlemen a convenient scapegoat for a pharma industry under pressure? In considering the alternative solutions, what are the prospects for legislative changes to control prices? What are the solutions for the current impasse?

    Jim Meyers, Executive Vice President ,Worldwide Commercial Operations, Gilead
    Steve Miller, Senior Vice President and Chief Medical Officer, Express Scripts 
    Aaron Kesselheim, Associate Professor of Medicine, Harvard Medical School
    Michael Rea, Founder and CEO, Rx Savings

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 11:10am
    Networking Coffee Break
  • 11:25am
    Panel: MACRA and Beyond: How Value is Transforming the Business Model of the Industry

    With strong bipartisan support, payment reform looks set to remain a mainstay of efforts to achieve more affordable and accountable care. Whilst we are still in the first innings in the move from fee-for-service to value- based care, the transition has already been game-changing across the industry-for payers, providers, life science companies, for patients and for the competitive landscape of the industry. Payments based on outcomes are expected to dwarf fee-for-service payments by 2020, and The Medicare Access & CHIP Re-authorization Act 2015 (MACRA) - the new system for medicare funded physicians based on outcomes - is expected to considerably accelerate the transformations already underway. What are the impacts and implications of MACRA? What have been the successes, challenges (for instance in the allocation of risks), margin impacts and learnings from the transition to date-the direct and indirect consequences of the payment reforms? What is the key to surviving and thriving in the new payment landscape?

    Ramita Tandon, Executive Vice President, CommercialiZation and Outcomes Services, ICON
    Anne Phelps, Principal, US Healthcare Regulatory Leader, Deloitte
    Douglas Henley, Executive Vice President and Chief Executive Officer, American Academy of Family Physicians
    David Lansky, Chief Executive Officer, Pacific Business Group on Health

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 12:15pm
    FT CEO Keynote Interview

    Steve Cutler, Chief Executive Officer, ICON

  • 12:35pm
  • 1:40pm
    Is the Future of Healthcare Virtual? Prospects for Home Care and Telehealth

    An ageing population, soaring healthcare costs, the rapid development in enabling technologies as well as supportive regulation and new payment models are driving interest and increased investment in telehealth and home care services. With the number of those aged 65 or older expected to increase at 5 times the rate of the rest of the population by until 2040, for instance the opportunity for savings in treating patients outside of the traditional hospital setting is significant. What is the business case/the ROI in investment in telehealth and home care? Will it ultimately increase, or decrease costs for the system? Will it lead to greater fragmentation of healthcare? What are the consumer expectations and preferences regarding care in the home? What are the implications for traditional healthcare providers- how can they reposition their business to accommodate for the changing delivery system?

    Roy Schoenberg, President and CEO, American Well
    Daniel Barchi, Senior Vice President and Chief Information Officer, New York Presbyterian Hospital
    Dedi Gilad, CEO and Co-Founder, Tyto Care
    Josh Bruno, Founder and CEO, Hometeam

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 2:20pm
    Tackling the Social Determinants of Health: The Next Big Challenge

    With the growing recognition that up to 40% of an individual’s health is determined by circumstances outside of the clinic, the government is encouraging healthcare companies to become more involved in influencing broader social determinants of health to include lack of housing, poverty, crime. A small but growing number of healthcare organizations are investing in such community benefit programs in line with evolving payment models supporting such activities. What are the societal determinants of health and which, if any, can health companies control? Are health companies, in reality, the best equipped to address social ills? How is the reimbursement regime payments regime evolving to support community benefit programs? How can outcomes be measured and attributed? What are the experiences of to date healthcare providers who have successfully embarked on such initiatives? Will we see these efforts spread more widely across the industry? 

    Robert Henkel, President and Chief Executive Officer, Ascension Health; Executive Vice President, Ascension
    Michelle Larkin, Associate Chief of Staff and Associate Vice President -Program, Robert Wood Johnson Foundation
    Damon Francis, Chief Medical Officer, Health Leads
    Tanisha Carino, Vice President, US Public Policy, GlaxoSmithKline

    Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 3:00pm
    Networking Coffee Break
  • 3:15pm
    Managing the Cost of Diabetes Care: Front Line Perspectives

    Many in the healthcare system recognize that some of the greatest opportunities for lowering costs of care and enhancing outcomes are centred around managing chronic diseases, and diabetes in particular as one of the more prevalent and costly chronic conditions. MACRA’s new payment system will also provide strong incentives to provide high quality care by paying bonuses for better results, and for innovations in care which keep diabetes under control. What strategies (e.g. clinical innovations, patient engagement strategies) are leading-edge organizations taking to improve care and control the costs of care for patients with the disease-the health plans and health systems that have high quality scores for diabetes care? What is and isn’t working?

    Jeff Dachis, CEO and Founder, One Drop
    Frank Westermann, Chief Executive Officer and Co-Founder, mySugr 
    Jose Peña, Chief Executive Officer and Chief Medical Officer, Rio Grande Valley ACO

    Moderator:Sarah Thomas, Managing Director, Deloitte Center for Health Solutions

  • 3:55pm
    Skills and Leadership for the New Health Economy: The Healthcare Workforce of the 21st Century

    From Chief Patient Officer to Health Coach to Physician Assistant and  beyond, roles and responsibilities in the healthcare system are evolving rapidly as new roles emerge, traditional professional boundaries converge, as digital technologies take root and as care moves from episodic to multi-disciplinary. What will the next generation healthcare workforce look like - how will the healthcare workforce be reshaped to fulfil the needs of the new health economy? Is the education system preparing the right type of graduates for the future? What will be the impact of robotics and artificial intelligence? Will robotics and automation do away with specific healthcare jobs?

    Al Prieto, Managing Partner, New York; Co-Global Practice Lead, Health, Egon Zehnder
    Julie Staudenmier, Senior Director Global Learning and Development, Pfizer
    Joseph Damore, Vice President, Population Health Management, Premier, Inc

    Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 4:35pm
    Beyond Genomics: Harnessing Innovation on the Frontiers of Science and Technology

    Healthcare is in the throes of a fast paced science and technology revolution. Individualized medicine, gene therapies, the microbiome, drone technology and advanced robotics are just some of the advanced technologies coming increasingly to the fore. This concluding session of the Summit will review the leading edge technologies advancing in the labs with the potential to transform health and personal care in the years ahead. Critical issues to include the ability of society to pay for such innovations will also be addressed by our panel of leading scientists, innovators and investors.

    Jeff Marrazzo, Co-Founder and CEO, Spark Therapeutics
    Noubar Afeyan,  Founder, Senior Managing Partner and CEO, Flagship Pioneering
    Jeffrey Riley, Chief Executive Officer, President and Director, Synthetic Biologics

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 5:15pm
    Closing Remarks from the Chair

Why Attend?

  • Gain insights into the next stage of reform and how the future of healthcare in the US will unfold.
  • Keep abreast of the next big thing in healthcare-tackling the social determinants of health.
  • Review the diverse strategies leading-edge companies are adopting to manage the cost and improve outcomes of diabetes care.
  • Understand the game-changing implications for payers, providers, and patients of MACRA and the accelerating transition from fee-for-service to value based care.
  • Don’t get left behind - be part of a must-attend event mapping the continuing transformation of healthcare.

Who Attends?

This event is for: CEOs, CFOs, CIOs, Chief Medical Officers, Chief Strategy Officers, Head Doctors, Heads of R&D, Emerging Markets, Consumer Health, Government Relations, Pricing, Regulation, Market Access, etc. and other senior-level executives in the following sectors:

  • Pharmaceuticals, Biotechnology, Generic and Specialty Pharmaceutical companies, Pharmacies
  • Medical Devices and Diagnostics
  • Investment (Fund Managers, Venture Capitalists, Private Equity firms, Investment Bankers, IP Groups, Health Insurance, Investment Banks)
  • Legal Counsel
  • Healthcare IT (Patient records, data, mobile healthcare applications, social media)
  • Regulation
  • Hospitals, Physician Networks, Healthcare providers
  • Government payers and Government agencies

With the support of (1)

About Life Sciences and Health Care at Deloitte

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability..

*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.

Lead sponsor (1)

ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, and to government. The company specialises in the strategic development, management and analysis of programs that support clinical development.  ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life. 

ICON has built a reputation as an industry innovator and expert in transforming pharma R&D through strategic partnerships and alliances. The company’s expertise in managing and interpreting large clinical and real-world data sets has led to its selection by organisations involved in key transformative projects, including the 100,000 Genomes Project, the world’s largest genome sequencing project for cancer and rare diseases. ICON has also been chosen by the International Consortium for Health Outcomes Measurement (ICHOM) to advance value-based healthcare through the creation of the world’s first global healthcare outcomes benchmarking program. 

With headquarters in Dublin, Ireland, ICON currently operates from 88 locations in 37 countries and has approximately 12,600 employees. For further information please visit Follow @iconplc on Twitter.

Associate Sponsors (2)

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 29,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 Innovation used to be the domain of R&D leaders, entrepreneurs and consultants, all chasing the next big thing. Today, with competition emerging from all corners—startups, legacy competitors, and even technology companies hungry for new markets—that former notion of innovation can no longer apply.
To succeed and survive today, healthcare CEOs and boards need to become masters of innovation, able to empower their people to unlock the best ideas, and then bring the best solutions to market.
At Egon Zehnder, we work with many of the world’s leading organizations to help them define and recruit the leadership teams need to succeed in today’s age of innovation and disruption. Through our partnership with Harvard Business School professor Linda A. Hill—a renowned expert on commercial innovation—we have developed the Innovation Quotient, a framework proven to help leaders catalyze the creativity necessary for their organization’s success.
Different from the traditional visionary qualities of leadership, innovative leaders are able to set in motion creative abrasion, agility and resolution that has been shown to lead to unexpected breakthroughs. Managing this process requires a unique set of leadership skills, including the ability to unleash the energy of the enterprise while also harnessing that power to meet concrete milestones and objectives.
We look forward to sharing our knowledge, and learning how your healthcare organization is innovating and competing in the face of constant disruption.

Breakfast briefing (1)

Diaceutics is a global group of experts from the laboratory, diagnostic and pharmaceutical industries. Bio: Our goal is to help pharmaceutical companies integrate diagnostic testing into their treatment pathways. We are empowered through a real-time flow of testing data from our worldwide laboratory network which we use to help our pharma clients understand and leverage the diagnostic landscape.

Diaceutics combines deep domain expertise with hands-on experience from over 200 diagnostic projects. Our digitally-enabled, proprietary Diaceutics Method® helps pharma companies master diagnostic launches and deliver a superior return on the diagnostic strategy. This is achieved by leveraging unique real-time lab analytics to ensure companies can segment their target physicians by testing behaviours. Diagnostic launches are implemented via our global lab network, providing pharma with rapid launches in the world’s top 10 markets.

Supporting Partner (2)

In 2011, StartUp Health introduced a revolutionary new model for transforming health by organizing and supporting a global army of entrepreneurs called Health Transformers (TM). The Company has identified and is investing in 10 Health Moonshots, with the long-term goal of improving the health and wellbeing of everyone in the world. With the world’s largest digital health portfolio (nearly 200 companies spanning 5 continents, 18 countries and 60+ cities), StartUp Health’s long-term platform for entrepreneurs includes the StartUp Health Academy, StartUp Health Network, StartUp Health Media and StartUp Health Ventures. Founded by Steven Krein and Unity Stoakes, StartUp Health is chaired by former Time Warner CEO Jerry Levin. To learn more, please visit

The International Lawyers Network is an association of 91 high-quality, full-service law firms with over 5,000 lawyers worldwide. The Network provides clients with easily accessible legal services in 67 countries on six continents.

Nearby Accommodation

We have put together a unique Hotel Map that shows hotel deals close to the event venue. To view, click here



Convene Conference Center
730 Third Avenue
NY 10017
New York

United States of America

Tel: (646) 854-7950



Tim Powell
Sponsorship Opportunities
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Chandni Saberwal
Media Partner & Press Inquiries
Financial Times
Funmbi Adenubi
Delegate Booking and Registration Enquiries
Financial Times